[go: up one dir, main page]

UY37854A - Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos - Google Patents

Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos

Info

Publication number
UY37854A
UY37854A UY0001037854A UY37854A UY37854A UY 37854 A UY37854 A UY 37854A UY 0001037854 A UY0001037854 A UY 0001037854A UY 37854 A UY37854 A UY 37854A UY 37854 A UY37854 A UY 37854A
Authority
UY
Uruguay
Prior art keywords
piperidina
diona
oxoisoindolin
derivatives
same
Prior art date
Application number
UY0001037854A
Other languages
English (en)
Inventor
Scott Visser Michael
Simone Bonazzi
Artiom Cernijenko
Aleem Fazal
Eric John Beckwith Rohan
Bhanudasji Tichkule Ritesh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY37854A publication Critical patent/UY37854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de fórmula (I'): O una sal, hidrato, solvato, profármaco, estereoisómero o tautómero farmacéuticamente aceptable del mismo, en donde R1, R2, Rx, X1, n, n1, y q son como se definen en el presente documento, así como métodos para fabricarlos y usarlos.
UY0001037854A 2017-08-23 2018-08-22 Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos UY37854A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762549225P 2017-08-23 2017-08-23

Publications (1)

Publication Number Publication Date
UY37854A true UY37854A (es) 2019-03-29

Family

ID=63638171

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037854A UY37854A (es) 2017-08-23 2018-08-22 Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos

Country Status (38)

Country Link
US (5) US10414755B2 (es)
EP (2) EP3672949B9 (es)
JP (1) JP7386787B2 (es)
KR (1) KR20200044038A (es)
CN (1) CN111051298B (es)
AR (1) AR112529A1 (es)
AU (3) AU2018319577B2 (es)
BR (1) BR112020003373B1 (es)
CA (1) CA3072694A1 (es)
CL (1) CL2020000427A1 (es)
CO (1) CO2020001860A2 (es)
CR (1) CR20200081A (es)
CU (1) CU20200014A7 (es)
DK (1) DK3672949T5 (es)
DO (1) DOP2020000037A (es)
EA (1) EA202090553A1 (es)
EC (1) ECSP20013248A (es)
ES (1) ES2940448T3 (es)
FI (1) FI3672949T3 (es)
HR (1) HRP20230244T1 (es)
HU (1) HUE061895T2 (es)
IL (1) IL272748B2 (es)
JO (1) JOP20200042A1 (es)
LT (1) LT3672949T (es)
MA (1) MA49952B1 (es)
MX (1) MX2020002060A (es)
PE (1) PE20200796A1 (es)
PH (1) PH12020500125A1 (es)
PL (1) PL3672949T3 (es)
PT (1) PT3672949T (es)
RS (1) RS64058B9 (es)
SA (1) SA520411325B1 (es)
SG (1) SG11202000490PA (es)
SI (1) SI3672949T1 (es)
TW (1) TWI793151B (es)
UY (1) UY37854A (es)
WO (1) WO2019038717A1 (es)
ZA (1) ZA202000208B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN109562107A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
KR20210003804A (ko) * 2018-04-13 2021-01-12 아비나스 오퍼레이션스, 인코포레이티드 세레브론 리간드 및 이를 포함하는 2작용성 화합물
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020012334A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
CA3119526A1 (en) 2018-12-03 2020-06-11 Dana-Farber Cancer Institute, Inc. Small molecule degraders of helios and methods of use
EP3897637A1 (en) * 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
ES2982474T3 (es) * 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
CN113490528B (zh) * 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CN113677664B (zh) * 2019-04-12 2025-04-04 C4医药公司 Ikaros和aiolos的三环降解物
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
MX2021014443A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
TW202108559A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
CR20220234A (es) * 2019-10-30 2022-07-19 Dana Farber Cancer Inst Inc Degradadores de moléculas pequeñas de helios y procedimientos de uso
CN110862395B (zh) * 2019-11-13 2020-09-29 株洲千金药业股份有限公司 一种制备他达拉非重要杂质的原料化合物的制备方法
BR112022009514A2 (pt) 2019-11-19 2022-08-16 Bristol Myers Squibb Co Compostos úteis como inibidores de proteína helios
TW202140441A (zh) * 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
AU2021262334B2 (en) * 2020-04-30 2023-12-14 Shanghaitech University Heterocycle and glutarimide skeleton-based compounds and applications thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20230357193A1 (en) * 2020-07-09 2023-11-09 Sichuan Haisco Pharmaceutical Co., Ltd. Compound capable of inhibiting and degrading androgen receptors, and pharmaceutical compositions and pharmaceutical uses thereof
US20240294489A1 (en) * 2020-08-03 2024-09-05 Captor Therapeutics S.A. Low molecular weight protein degraders and their applications
WO2022029573A1 (en) * 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022066835A1 (en) 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
EP4225749A4 (en) * 2020-10-07 2025-05-14 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
JP2023545508A (ja) * 2020-10-14 2023-10-30 シーフォー セラピューティクス， インコーポレイテッド Ｉｋｚｆ２又はｉｋｚｆ４を分解する三環式リガンド
CN116669769A (zh) * 2020-10-16 2023-08-29 达纳－法伯癌症研究所公司 Helios的哌啶基小分子降解剂和使用方法
JP2023545396A (ja) * 2020-10-16 2023-10-30 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Ｈｅｌｉｏｓのピペリジニル低分子分解剤および使用方法
WO2022120355A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
UY39671A (es) * 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
SMT202500281T1 (it) 2021-04-06 2025-09-12 Bristol Myers Squibb Co Composti ossoisoindolinici sostituiti con piridinile
CA3215907A1 (en) * 2021-04-29 2022-11-03 Whitney L. PETRILLI Substituted 2-(2,6-dioxopiperidin-3-yl)-5-(1-piperidin-4-yl)isoindoline-1,3-dione derivatives and uses thereof
AU2022265693A1 (en) * 2021-04-29 2023-09-07 Dana-Farber Cancer Institute, Inc. Phthalimido cereblon complex binders and transcription factor degraders and methods of use
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
JP2024528988A (ja) 2021-08-06 2024-08-01 セルジーン コーポレーション 改変タンパク質の選択的分解のための組成物および方法
EP4385985A1 (en) * 2021-08-11 2024-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Heterocyclic derivative, and composition and pharmaceutical use thereof
CA3235512A1 (en) * 2021-10-22 2023-04-27 Xiaobao Yang Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CR20240173A (es) 2021-10-29 2024-06-20 Gilead Sciences Inc Compuestos de cd73
JP2024546851A (ja) 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CN116640122A (zh) * 2022-02-16 2023-08-25 苏州国匡医药科技有限公司 Ikzf2降解剂及包含其的药物组合物和用途
JP2025509610A (ja) 2022-03-17 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
TW202345797A (zh) * 2022-03-25 2023-12-01 美商昂科皮治療公司亦以普羅提歐凡治療公司名稱營業 作為ｉｋｚｆ２降解劑之含雙環雜芳基化合物
US20250215012A1 (en) * 2022-03-25 2025-07-03 Regents Of The University Of Michigan Ikzf2 degraders and uses thereof
WO2023201012A1 (en) * 2022-04-15 2023-10-19 Regents Of The University Of Michigan Ikzf2 degraders and uses thereof
JP2025513258A (ja) 2022-04-21 2025-04-24 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａ ｇ１２ｄ調節化合物
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc CD73 compounds
CN117881668A (zh) * 2022-08-10 2024-04-12 标新生物医药科技(上海)有限公司 基于异吲哚啉取代戊二酰亚胺骨架的化合物及其应用
US20260021103A1 (en) * 2022-09-14 2026-01-22 President And Fellows Of Harvard College Ikzf2 and ck1-alpha degrading compounds and uses thereof
WO2024120438A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 一种固体分散体、其制备方法和应用
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
EP4660193A1 (en) 2023-01-31 2025-12-10 Korea Research Institute of Chemical Technology Indole compound decomposing ikzf2, and use thereof
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025067466A1 (zh) * 2023-09-28 2025-04-03 杭州多域生物技术有限公司 一种杂环化合物、其组合物及应用
WO2025076284A1 (en) * 2023-10-06 2025-04-10 Delphia Therapeutics, Inc. Compounds, pharmaceutical compositions thereof, and methods of using the same
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245178A1 (en) * 2024-05-21 2025-11-27 Innovo Therapeutics, Inc. Pak4, cstf2, or cstf2t protein degraders, pharmaceutical compositions, and therapeutic applications
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
US7196170B2 (en) 1992-09-14 2007-03-27 The General Hospital Corporation Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
EP1285916B1 (en) 1996-07-24 2010-03-10 Celgene Corporation Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels
AU2001291195A1 (en) 2000-12-01 2002-06-11 Parker Hughes Institute Nucleotide and protein sequence of helios 3 and methods of use
JP4196678B2 (ja) 2001-04-26 2008-12-17 味の素株式会社 複素環化合物
AU2002323063B2 (en) 2001-08-06 2007-11-08 Entremed, Inc. Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7612096B2 (en) 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20070161696A1 (en) 2004-04-23 2007-07-12 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
KR20070057907A (ko) * 2004-09-03 2007-06-07 셀진 코포레이션 치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린의제조 방법
JP4731867B2 (ja) 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
US8394832B2 (en) 2004-12-01 2013-03-12 Celgene Corporation Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
EP1824997B1 (en) 2004-12-10 2010-09-15 Siemens Healthcare Diagnostics GmbH Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment
WO2007067500A2 (en) 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
EP1974013A2 (en) 2005-12-29 2008-10-01 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
ES2336625T3 (es) 2006-03-22 2010-04-14 Vertex Pharmaceuticals Incorporated Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
US20070269827A1 (en) 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
KR101342035B1 (ko) 2006-06-20 2013-12-16 한국과학기술연구원 신장독성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 신장독성 및 부작용 유발 약물 검색 방법
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
JP2009092508A (ja) 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
US20100247580A1 (en) 2007-11-30 2010-09-30 Thierry Coche Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy
KR100957051B1 (ko) 2007-12-28 2010-05-13 한국과학기술연구원 니트로푸란토인 처리에 따른, 폐독성 유발 약물 검색용마커유전자 및 이를 이용한 검색 방법
GB2456390A (en) 2008-01-15 2009-07-22 Glaxo Group Ltd Bipolar disorder treatments
WO2009094592A2 (en) 2008-01-23 2009-07-30 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
CA2718887A1 (en) 2008-03-19 2009-09-24 Existence Genetics Llc Genetic analysis
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
MX2012001504A (es) 2009-08-05 2012-06-01 Versitech Ltd Compuestos antivirales y metodos para elaborarlos y usarlos.
US9752196B2 (en) 2009-10-26 2017-09-05 Abbott Molecular Inc. Detection of chromosomal abnormalities associated with prognosis of non small cell lung cancer
CA2799165C (en) 2010-05-12 2022-04-12 Steven E. Schutzer Diagnostic markers for neuropsychiatric disease
US20120149715A1 (en) 2010-05-28 2012-06-14 Yi Tsun Richard Kao Compounds and methods for the treatment of viral infections
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US20130281304A1 (en) 2010-08-13 2013-10-24 Andrew P. Feinberg Comprehensive Methylome Map of Myeloid and Lymphoid Commitment from Hematopoietic Proenitors
JP2014502258A (ja) 2010-10-22 2014-01-30 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 免疫反応を抑制するためにプログラムされた制御性ｔ細胞の発見
JP6001060B2 (ja) 2011-06-06 2016-10-05 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 筋萎縮を阻害するための方法
WO2012175613A1 (en) 2011-06-21 2012-12-27 Innate Pharma NKp46-MEDIATED NK CELL TUNING
KR102107862B1 (ko) 2011-07-01 2020-05-07 베크만 컬터, 인코포레이티드 조절 t 세포, 및 cd6-발현 또는 cd4, cd25 및 cd127의 조합을 사용하여 이를 확인 및 단리하는 방법
WO2013037118A1 (zh) 2011-09-16 2013-03-21 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
DK3569690T3 (da) 2011-12-01 2024-11-11 Univ Tokyo Human-afledte bakterier som inducerer proliferation eller akkumulation af regulatoriske t-celler
US9481866B2 (en) 2011-12-16 2016-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations enriched for stable regulatory T-cells
IN2014CN04935A (es) 2011-12-31 2015-09-18 Moni Abraham Kuriakose
US9801911B2 (en) 2012-03-02 2017-10-31 The Regents Of The University Of California Expansion of alloantigen-reactive regulatory T cells
GB201207297D0 (en) 2012-04-26 2012-06-06 Senzagen Ab Analytical methods and arrays for use in the same
GB201213571D0 (en) 2012-07-31 2012-09-12 Univ Leuven Kath Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal
EP2682750A1 (en) 2012-07-02 2014-01-08 Sotio a.s. In vitro method for the diagnosis and surveillance of cancer
EP2903692B1 (en) 2012-10-08 2019-12-25 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
US20160007893A1 (en) 2013-02-06 2016-01-14 Loxbridge Research Llp Systems and methods for early disease detection and real-time disease monitoring
EP2970881A4 (en) 2013-03-14 2017-01-25 Children's Medical Center Corporation Compositions and methods for reprogramming hematopoietic stem cell lineages
BR112015022490A2 (pt) 2013-03-15 2017-07-18 Veracyte Inc métodos e composições para classificação de amostras
US20160122821A1 (en) 2013-06-10 2016-05-05 Suregene, Llc Genetic markers of antipsychotic response
GB2532672A (en) 2013-09-09 2016-05-25 Scripps Research Inst Methods and systems for analysis of organ transplantation
WO2015050875A1 (en) 2013-10-01 2015-04-09 The Regents Of The University Of California Endometriosis classifier
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2015107196A1 (en) 2014-01-20 2015-07-23 Institut Curie Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2015160845A2 (en) * 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP3227464B1 (en) 2014-12-05 2022-04-20 Foundation Medicine, Inc. Multigene analysis of tumor samples
EP3034620A1 (en) 2014-12-17 2016-06-22 Diaxonhit Compositions and methods for diagnosing thyroid cancer
WO2016103269A1 (en) 2014-12-23 2016-06-30 Ramot At Tel-Aviv University Ltd. Populations of neural progenitor cells and methods of producing and using same
AU2016209321B2 (en) 2015-01-20 2019-05-09 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds, compositions and method of using thereof
EP3050570A1 (en) 2015-01-31 2016-08-03 Neurovision Pharma GmbH Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF
WO2016140974A1 (en) 2015-03-01 2016-09-09 Novena Therapeutics Inc. Process for measuring tumor response to an initial oncology treatment
EP3298004B1 (en) 2015-05-22 2021-01-06 Biotheryx Inc. Compounds targeting proteins, compositions, methods, and uses thereof
WO2016196580A1 (en) 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
WO2016196912A1 (en) 2015-06-03 2016-12-08 Dana-Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
CN108135945A (zh) 2015-06-22 2018-06-08 哈佛大学校长及研究员协会 固有层调节性t细胞的诱导
WO2017042337A1 (en) 2015-09-09 2017-03-16 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmhotz-Gemeinschaft Short-chain fatty acids for use in the treatment of cardiovascular disease
WO2017044979A2 (en) 2015-09-11 2017-03-16 Ventria Bioscience Inc. Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
EP3356346B1 (en) 2015-09-30 2024-11-06 THE UNITED STATES OF AMERICA, as represented by the Secretary, DEPARTMENT OF HEALTH AND HUMAN SERVICES Thalidomide analogs and methods of use
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
EP3384013A4 (en) 2015-12-04 2019-07-10 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ANTIGEN-SPECIFIC T CELLS FOR INDUCING IMMUNOTOLERANCE
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
US10584101B2 (en) 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
KR20250117470A (ko) 2016-12-23 2025-08-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
JP7266526B6 (ja) 2017-01-26 2024-02-15 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体タンパク質分解性の調節因子およびその関連方法
CN106932576A (zh) 2017-03-22 2017-07-07 山东大学深圳研究院 一种人调节性t细胞的免疫抑制功能的检测方法
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途

Also Published As

Publication number Publication date
US20190062309A1 (en) 2019-02-28
IL272748A (en) 2020-04-30
MX2020002060A (es) 2020-07-13
CO2020001860A2 (es) 2020-05-29
US10647701B2 (en) 2020-05-12
PL3672949T3 (pl) 2023-05-08
US20210309638A1 (en) 2021-10-07
SI3672949T1 (sl) 2023-04-28
PH12020500125A1 (en) 2020-09-14
BR112020003373A2 (pt) 2020-08-25
CU20200014A7 (es) 2020-11-30
AR112529A1 (es) 2019-11-06
JP7386787B2 (ja) 2023-11-27
DK3672949T5 (da) 2023-05-01
EP3672949B1 (en) 2022-12-21
JOP20200042A1 (ar) 2020-02-20
RS64058B1 (sr) 2023-04-28
EP4183782A1 (en) 2023-05-24
AU2022231670A1 (en) 2022-10-06
TWI793151B (zh) 2023-02-21
WO2019038717A1 (en) 2019-02-28
PT3672949T (pt) 2023-03-16
AU2020277231A1 (en) 2020-12-24
EP3672949A1 (en) 2020-07-01
EP3672949B9 (en) 2023-04-05
DK3672949T3 (da) 2023-03-27
ES2940448T3 (es) 2023-05-08
US11053218B2 (en) 2021-07-06
MA49952B1 (fr) 2023-03-31
AU2018319577A1 (en) 2020-02-06
PE20200796A1 (es) 2020-08-10
US10414755B2 (en) 2019-09-17
JP2020531498A (ja) 2020-11-05
KR20200044038A (ko) 2020-04-28
TW201920143A (zh) 2019-06-01
SG11202000490PA (en) 2020-03-30
ZA202000208B (en) 2021-07-28
IL272748B2 (en) 2023-02-01
AU2018319577B2 (en) 2020-10-15
CN111051298B (zh) 2023-06-27
HUE061895T2 (hu) 2023-08-28
RS64058B9 (sr) 2023-08-31
CN111051298A (zh) 2020-04-21
CA3072694A1 (en) 2019-02-28
CR20200081A (es) 2020-05-14
RU2020111556A3 (es) 2021-12-17
US20190367483A1 (en) 2019-12-05
BR112020003373B1 (pt) 2022-08-09
EA202090553A1 (ru) 2020-06-08
US10640489B2 (en) 2020-05-05
MA49952A (fr) 2021-04-28
HRP20230244T1 (hr) 2023-04-14
US20190359594A1 (en) 2019-11-28
CL2020000427A1 (es) 2020-08-28
RU2020111556A (ru) 2021-09-23
LT3672949T (lt) 2023-04-11
SA520411325B1 (ar) 2022-06-13
US20200231569A1 (en) 2020-07-23
FI3672949T3 (fi) 2023-03-23
DOP2020000037A (es) 2020-08-15
ECSP20013248A (es) 2020-05-29
IL272748B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
UY38296A (es) Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
EA201791304A1 (ru) Производные изохинолина для лечения вич
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
CU20170007A7 (es) Compuestos de imidazopiridazina
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231110